Symbol="AKTX"
AssetType="Common Stock"
Name="Akari Therapeutics PLC"
Description="Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom."
CIK="1541157"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="24 WEST 40TH STREET, 8TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2022-06-30"
MarketCapitalization="17321200"
EBITDA="-23084500"
PERatio="None"
PEGRatio="0"
BookValue="0.024"
DividendPerShare="0"
DividendYield="0"
EPS="-0.29"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-1.133"
ReturnOnEquityTTM="-4.832"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.29"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="2.75"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="3.432"
EVToRevenue="-"
EVToEBITDA="-1.11"
Beta="1.289"
num_52WeekHigh="1.61"
num_52WeekLow="0.14"
num_50DayMovingAverage="0.174"
num_200DayMovingAverage="0.361"
SharesOutstanding="101116000"
DividendDate="None"
ExDividendDate="None"
symbol="AKTX"
open="0.18"
high="0.18"
low="0.17"
price="0.17"
volume="171254.00"
latest_trading_day="2023-07-14"
previous_close="0.18"
change="-0.01"
change_percent="-5.4636%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Strong Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="489453"
Change_recent_avg="-0.01"
Delta_recent_avg="0.03"
Variance_recent_avg="0.01"
Change_ratio_recent_avg="-2.6"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="1129"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0162.jpeg"
image_negative_thumbnail_id_2="145"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0031.jpeg"
image_neutral_thumbnail_id_1="584"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0015.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="962"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0124.jpeg"
image_positive_thumbnail_id_2="704"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0004.jpeg"
image_professor_thumbnail_id_1="1197"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0031.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
